Albany, NY -- (SBWIRE) -- 07/22/2019 -- Alopecia Areata Market Insights, Epidemiology and Market Forecast-2028
1. Approximately 2.5 million people are suffering from Alopecia Areata in the United States.
2. Alopecia Areata affects approximately two per cent of the general population at some point during their lifetime.
3. Alopecia Areata prevalence is estimated to be 0.1–0.2% in the general population.
DelveInsight launched a new report on Alopecia Areata Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Alopecia Areata market report covers a descriptive overview and comprehensive insight of the Alopecia Areata epidemiology and Alopecia Areata market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Alopecia Areata market report provides insights on the current and emerging therapies.
3. Alopecia Areata market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Alopecia Areata market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alopecia Areata market.
Request for sample pages
"Alopecia Areata patients experience their first onset by age 40 years in 82.6–88% of patients and by age 20 years in 40.2% of patients."
The alopecia areata is the most common form of alopecia and is characterized by patchy scalp baldness. The potential for hair recovering is maintained but, at present, there is no treatment able to induce a permanent remission of this disease. Thus, alopecia areata market is completely dominated by off-label drug therapies. Depending on the extent of hair loss and age, there are a variety of alopecia areata treatment options available.
There are many therapies which are being used for the management of the alopecia areata, but they often are ineffective and causes significant downsides. As observed, folliculitis is the common adverse event of topical corticosteroids. Biologic agents are used in alopecia areata treatment, but many studies show that some patients developed alopecia areata while undertaking treatment for other conditions. Systemic therapy also causes a number of adverse effects like diabetes, weight gain, hypertension, psychological changes, osteoporosis, suppression of the adrenocorticotropic axes, striae, - acne, hypertrichosis, and purpura, etc. The disease may independently remit, and it is challenging to predict how long patients will take new therapies. It is also unclear how targeted agents will be used across patient populations of different disease severity. So, there is a high unmet need for new therapies that can overcome these limitations.
The market drivers of alopecia areata market are genetics or hereditary linkages, rising prevalence of cancer and an increase in research and development activities. Genetics is the major factor driving the growth of alopecia areata drugs market across the globe. Apart from that, the rising prevalence of cancer and its treatment methods such as chemotherapy leads to heavy hair loss that results in the increasing demand for hair loss therapies. Moreover, increasing research and development activities are some of the factors which are expected to contribute toward the market growth during the forecast period (2019–2028).
In the coming years, the competitive landscape for the Alopecia Areata market is set to change due to raising awareness of the disease, and incremental healthcare spending across the world; which would expand Alopecia Areata market size to enable the drug manufacturers to penetrate more into Alopecia Areata market.
Major players such as
1. Pfizer
2. LEO Pharma
3. Legacy Healthcare SA
4. Aclaris Therapeutics
5. Concert Pharmaceuticals
6. Energenesis Biomedical
and many others
The launch of emerging therapies that will significantly impact the Alopecia Areata market during the study period (2017–2028) are:-
1. PF-06651600 and PF-06700841
2. LH-8
3. ATI-502
4. CTP-543
5. ENERGI-F701
and many others
Table of contents
1. Report Introduction
2. Alopecia Areata Market Overview at a Glance
3. Alopecia Areata Disease Background and Overview
4. Alopecia Areata Epidemiology and Patient Population
5. Alopecia Areata Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
6. Alopecia Areata Treatments & Medical Practices
7. Alopecia Areata Emerging Therapies
7.1. Key Cross Competition
7.2. LH-8/ Charité: Legacy Healthcare SA
7.3. PF – 06651600: Pfizer
7.4. ATI50002: Aclaris Therapeutics
8. Alopecia Areata Market Size
9. 7MM Alopecia Areata Country-Wise Market Analysis
9.1. United States Market Size
9.2. Germany Market Size
9.3. France Market Size
9.4. United Kingdom Market Size
9.5. Spain Market Size
9.6. Italy Market Size
9.7. Japan Market Size
10. Alopecia Areata Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight